CEO
BRIJ Medical
BRIJ Medical provides a comprehensive incision management system for surgical closure, featuring Brijjit® Force Modulating Tissue Bridges that actively offload up to 100% of incisional tension and BRIJ-SEAL™, a hypoallergenic wound closure device offering a 14-day bacterial barrier against MRSA and VRE. The products are designed for fast application, gentle removal, and extended wear times of 10-14+ days, with clinical data showing a 90% reduction in open wound incidence and a 38% reduction in scar area.
- Medical Devices
- Healthcare Technology
- Hardware
Updated yesterday
Funding
Raised to date
$16MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 5 rounds
TGTGVC
$5M · Undisclosed
Announced Nov 2026 · from article date
Disclosed cumulative: $10.5M
4/4
Not on chart (date unknown): Seed $5.5M
RoundDateAmountValuationInvestors
Founders
Product
Problem
Post-surgical incisions and traumatic wounds are prone to tension-induced breakdown, excessive scarring, and allergic reactions to traditional skin adhesives, leading to higher complication rates and additional patient visits.
Solution
BRIJ Medical offers a comprehensive incision management system comprising two complementary products. Brijjit® Force Modulating Tissue Bridges are biocompatible, non-invasive skin closure devices that actively offload incisional tension up to 100% while remaining on the surface of the skin, applied as the final layer of closure after deep dermal sutures. BRIJ-SEAL™ is a single-use, sterile, hypoallergenic wound closure device that provides a 14-day bacterial barrier against six organisms including MRSA, VRE, and P. aeruginosa, and can be used alone or paired with Brijjit for active tension offloading. Both products use the same hypoallergenic adhesive technology that demonstrated no reported allergic reactions across six clinical studies. The devices are breathable, waterproof, and designed for wear times of 10-14+ days, with fast application and gentle removal that can be performed at the bedside or by patients at home.
Target Audience
Primary customers are plastic surgeons, orthopedic surgeons, podiatric surgeons, and emergency/urgent-care clinicians who perform incision closure and seek to minimize wound complications and scarring. The products are also used by hospital networks and healthcare systems across the U.S. and Canada.
Features
- Active tension offloading up to 100% at and below the skin surface via force-modulating tissue bridges, reducing tissue force concentration approximately 200-fold compared with sutures in preclinical finite element modeling
- Non-invasive, surface-applied device that replaces the final suture layer and is applied up to 9x faster than sutures
- BRIJ-SEAL provides a 14-day bacterial barrier against six organisms including MRSA, VRE, and P. aeruginosa as verified by independent lab testing
- Hypoallergenic adhesive with no cyanoacrylates and no reported allergic reactions in six clinical trials
- Waterproof, breathable material that allows moisture vapor to escape and permits showering per surgeon instructions
- Wear time of 10-14+ days, compatible with compression garments for extended support
- Reduces open wound incidence by 90% and scar area by 38% as shown in multiple RCTs
- Available in two sizes of Brijjit bridges and one size of BRIJ-SEAL (28cm x 5cm) to accommodate a range of incision lengths